Frontlight ResearchEarly access
Polycystic kidney disease trials in Poland
1 trial · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3CompletedA Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Where
- Bialystok, Warsaw
- Age
- 28 days to 18 years
- People
- 20 worldwide
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT04782258 · EU 2023-508218-41-00